Updated:
Codexis
Codexis is a company that provides RNA manufacturing and custom enzyme engineering for pharmaceuticals and siRNA therapeutics. They offer enzyme-enabled...
Codexis
Codexis is a company that provides RNA manufacturing and custom enzyme engineering for pharmaceuticals and siRNA therapeutics. They offer enzyme-enabled platforms for therapeutic manufacturing, including RNA manufacturing, pharma biocatalysis, and molecular biology and diagnostic applications. The company has spent over 20 years refining the science of enzyme engineering and redefining the boundaries of its therapeutic potential.
General information
Firm type
other
Year founded
2002
Location
Region
North America
Country
United States
City
Redwood City
Corporate office
Redwood City, CA, United States
Principals
Stephen Dilly
Executive Chairman
Georgia Erbez
Chief Financial Officer and Chief Business Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Codexis?
Stephen Dilly serves as Executive Chairman, overseeing strategic direction. Georgia Erbez is CFO and Chief Business Officer, managing financial operations and business development.
Is Codexis structured as a family office or a publicly traded company?
Codexis is a publicly traded enzyme engineering company (NASDAQ: CDXS). It is not a family office.
What investment stages does Codexis target?
Codexis does not make investments. It provides enzyme engineering and manufacturing services to pharmaceutical, biotech, and diagnostic clients across R&D and commercial stages.
Which sectors does Codexis explicitly avoid?
The firm does not publicly disclose exclusions beyond its stated focus on RNA manufacturing, pharma biocatalysis, and diagnostics. It does not operate in consumer goods or agricultural enzyme markets.
How does Codexis source proprietary deal flow?
Codexis originates business through direct partnerships with pharmaceutical and biotech companies seeking enzyme engineering for drug manufacturing and diagnostics. The firm also engages with academic institutions and research organizations.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: